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Introduction
Lipin 1 is a bifunctional protein that regulates metabolism by interacting with DNA-bound transcription fac-
tors (1) and also exhibiting Mg2+-dependent phosphatidic acid phosphohydrolase (PAP) activity (2). At the 
endoplasmic reticulum membrane, PAP enzymes dephosphorylate phosphatidic acid (PA) to form diacylglyc-
erol (DAG) (Figure 1A), which is the penultimate step in triglyceride synthesis. In higher organisms, 3 lipin 
proteins (lipin 1, 2, and 3) are encoded by distinct genes. The lipin isoforms are differentially expressed in var-
ious tissues, with lipin 1 being the primary isoform in adipose tissue and in skeletal and cardiac muscle (3, 4).
In mice, mutations in lipin 1 result in neonatal hepatic steatosis and life-long lipodystrophy, insulin resis-
tance, and progressive peripheral neuropathy (5, 6). However, mutations in the human gene encoding lipin 1 
(LPIN1) do not result in a similar phenotype but have been linked to the development of recurrent, early-onset, 
pediatric rhabdomyolysis and myoglobinuria (OMIM #268200) (7–10). Rhabdomyolysis is an acute syndrome 
due to extensive injury of skeletal muscle resulting in the release of intracellular metabolites and proteins, 
including creatine kinase and myoglobin, into the systemic circulation. Untreated rhabdomyolysis can result 
in death from renal, cardiac, or hematologic dysfunction. Several deaths of LPIN1 patients have been reported 
during rhabdomyolytic episodes, likely due to cardiac events (11). Work conducted with fld (12) and skeletal 
muscle–specific Lpin1-KO (13, 14) mice has revealed that loss of lipin 1 in muscle of mice leads to active and 
ongoing myopathy that is secondary to impairments in autophagy. This phenotypic manifestation diverges 
from the acute and nonprogressive nature of the human mutation, but it could be mechanistically linked.
Lipin 1 is a bifunctional protein that is a transcriptional regulator and has phosphatidic acid 
(PA) phosphohydrolase activity, which dephosphorylates PA to generate diacylglycerol. 
Human lipin 1 mutations lead to episodic rhabdomyolysis, and some affected patients exhibit 
cardiac abnormalities, including exercise-induced cardiac dysfunction and cardiac triglyceride 
accumulation. Furthermore, lipin 1 expression is deactivated in failing heart, but the effects of 
lipin 1 deactivation in myocardium are incompletely understood. We generated mice with cardiac-
specific lipin 1 KO (cs-Lpin1–/–) to examine the intrinsic effects of lipin 1 in the myocardium. 
Cs-Lpin1–/– mice had normal systolic cardiac function but mild cardiac hypertrophy. Compared with 
littermate control mice, PA content was higher in cs-Lpin1–/– hearts, which also had an unexpected 
increase in diacylglycerol and triglyceride content. Cs-Lpin1–/– mice exhibited diminished cardiac 
cardiolipin content and impaired mitochondrial respiration rates when provided with pyruvate or 
succinate as metabolic substrates. After transverse aortic constriction–induced pressure overload, 
loss of lipin 1 did not exacerbate cardiac hypertrophy or dysfunction. However, loss of lipin 1 
dampened the cardiac ionotropic response to dobutamine and exercise endurance in association 
with reduced protein kinase A signaling. These data suggest that loss of lipin 1 impairs cardiac 
functional reserve, likely due to effects on glycerolipid homeostasis, mitochondrial function, and 
protein kinase A signaling.
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Lpin1 is well expressed in the myocardium and may play a role in this metabolically active organ. Previ-
ous work has shown that lipodystrophic, lipin 1–deficient fld mice exhibit cardiac dysfunction, though this 
was attributed to extracardiac factors and secondary to systemic alterations in metabolism (3). Recently, 
Legendre and colleagues examined cardiac function in 8 human patients with LPIN1 mutations and found 
that cardiac function was normal in all but 1 of  the patients at rest, but 3 of  the subjects exhibited abnormal 
hemodynamics during exercise (15). The reasons for this impaired hemodynamic response were not defini-
tively determined, but they may be related to energetic defects. LPIN1 patients also exhibited accumulation 
of  neutral lipid within the myocardium (15), and cardiac lipotoxicity has been implicated in the develop-
ment of  cardiac dysfunction in a variety of  models (16, 17).
In this study, we show that cardiac lipin 1 expression is downregulated in human heart failure 
specimens. We also examined the role of  lipin 1 in cardiac function, signaling, and metabolism by gen-
erating mice with cardiac-specific deletion of  lipin 1. This approach was chosen in order to avoid the 
systemic effects of  lipin deficiency on metabolic homeostasis. We found that, like most LPIN1 patients, 
cardiac-specific loss of  Lpin1 in mice (cs-Lpin1–/– mice) did not result in overt cardiac dysfunction. 
However, cs-Lpin1–/– mice exhibited cardiac lipid accumulation and a blunted ionotropic response to 
dobutamine. Loss of  lipin 1 led to impaired maximal mitochondrial respiration, reduced cardiolipin 
(CL) abundance, and attenuated protein kinase A (PKA) signaling. These data unveil potentially nov-
el, cardiac-specific roles for lipin 1 in regulating cardiac lipid metabolism and contractile function in 
response to hemodynamic stress.
Figure 1. Lipin 1 is deactivated in failing human heart. (A) The schematic depicts the sequential acylation of glycer-
ol-3-phosphate (G3P) to generate triglyceride. LPA, lysophosphatidic acid; PA, phosphatidic acid; DAG, diacylglycerol; CDP, 
cytosine diphosphate; PI, phosphatidylinositol; PG, phosphatidylglycerol; CL, cardiolipin; PC, phosphatidylcholine; PE, phos-
phatidylethanolamine; PS, phosphatidylserine. (B and C) Lipin 1 protein abundance (B) and mRNA expression (C) is signifi-
cantly diminished in cardiac tissue of people with heart failure. Densitometry for the sum of both lipin 1 bands (normalized 
arbitrary units) is inset between the blots. Data represent mean ± SEM. *P < 0.05 by t test (n = 15 and 9/group).
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Results
The expression of  LPIN1 is deactivated in human heart failure. The protein abundance of  lipin 1 and expression 
of  LPIN1 and LPIN2 mRNA were quantified in heart samples from humans with heart failure, obtained at 
the time of  left ventricular assist device (LVAD) implantation. Failing heart tissue was compared with cardi-
ac tissue from donor hearts that were nonfailing but deemed unsuitable for transplant. Immunoblots using 
human heart lysates and an antibody against lipin 1 detected a doublet at approximately 130 kDa (Figure 
1B; see complete unedited blots in the supplemental material; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.134340DS1). This is often observed, and this doublet is 
due to the phosphorylated and dephosphorylated forms of  the protein (18). We have shown that mutations 
in lipin 1 lead to a loss of  both bands in human skeletal muscle lysates (9). We found that the protein abun-
dance of  both lipin 1 bands was decreased by nearly 50% in failing hearts compared with normal functioning 
controls (Figure 1B). In addition, the mRNA encoding lipin 1 (LPIN1) was also reduced in failing hearts 
compared with controls, whereas the expression of  LPIN2 tended to be increased (Figure 1C). However, it 
should be noted that, based on the Ct values obtained, LPIN2 is expressed at much lower levels than LPIN1 
in myocardium (data not shown), consistent with low expression of  this gene in heart (4).
Generation of  cardiac-specific Lpin1-KO mice. To characterize the effects of  lipin 1 in the heart and avoid 
the systemic metabolic abnormalities present in mice with constitutive lipin 1 deficiency, we generated 
cs-Lpin1–/– mice using recently described Lpin1-floxed mice (14) and mice expressing Cre under the control 
of  the cardiac myosin light chain 2v promoter. Homozygous cs-Lpin1–/– mice were viable and outwardly 
normal. Quantification of  Lpin1 mRNA expression showed a dramatic decrease in expression of  this gene 
in cs-Lpin1–/– heart compared with littermate controls not expressing Cre (WT; Figure 2A). Cardiac expres-
sion of  lipin 1 protein was also markedly diminished in the KO mice compared with floxed controls not 
expressing Cre (denoted as WT) (Figure 2B). However, there was residual expression of  lipin 1 protein in 
some hearts, likely due to expression in cells other than cardiac myocytes or incomplete recombination 
at the time point examined. Protein lysates from hearts of  mice constitutively lacking lipin 1 (fld) showed 
complete loss of  lipin 1 protein (Figure 2B).
Cardiac lipin 1 deficiency does not lead to contractile dysfunction or myocyte death. At sacrifice, biventricular 
weights were measured, and it was found that the biventricular/body mass ratio was not affected (Figure 
2C). However, a significant increase in the cardiac expression of  the fetal gene markers of  hypertrophy 
(Nppa, Nppb, Myh7, and Acta1) in cs-Lpin1–/– mice compared with littermate controls was identified (Figure 
2D). Echocardiographic characterization of  cardiac mass and function revealed no evidence of  cardiac 
hypertrophy in 10-week-old male or female cs-Lpin1–/– mice compared with littermate controls, nor were 
any deficits in systolic function detected (Table 1).
We have recently shown that deletion of  lipin 1 in skeletal muscle of  mice impairs autophagy and accu-
mulation of  abnormal mitochondria, and it produces active myopathy, including loss of  skeletal myocytes to 
necrotic cell death, macrophage infiltration, and sterile inflammation of  muscle (14). Histologic evaluation 
of  cardiac sections from cs-Lpin1–/– mice found no evidence of  these myopathic changes (Figure 2E), nor 
was the expression of  gene markers for these processes elevated (Figure 2F). Electron microscopy of  cardiac 
mitochondria from cs-Lpin1–/– mice showed no ultrastructural abnormalities of  mitochondria (Figure 2G).
Cardiac lipid accumulation in hearts of  cs-Lpin1–/– mice. Recent work conducted using 1H-MRS has sug-
gested that LPIN1 patients exhibit accumulation of  cardiac triglyceride (15). We used mass spectrometry 
to quantify cardiac PA, DAG, and triglyceride species. We found that several species of  PA and total PA 
abundance was increased in hearts of  cs-Lpin1–/– mice compared with littermate controls (Figure 3A). The 
abundance of  DAG and triglyceride, including most of  the major species measured (Figure 3, B and C), 
was counterintuitively increased in hearts of  cs-Lpin1–/– mice. However, this is consistent with recent results 
obtained in skeletal muscle-specific Lpin1–/– mice (13, 14) and human LPIN1 patients (15). Interestingly, the 
abundance of  CL, a lipid that plays an important role in regulating mitochondrial oxidative metabolism, 
was decreased in cs-Lpin1–/– mice compared with WT controls (Figure 3D). These data show that cardi-
ac-specific lipin 1 deletion leads to an alteration in the abundance of  several lipid species in the heart.
Diminished mitochondrial respiration in hearts of  cs-Lpin1–/– mice. Diminished CL and accumulation of  
lipid in the myocardium with lipin 1 deficiency could suggest impairments in mitochondrial oxidative func-
tion. Consistent with this, metabolomic analyses of  myocardium after an overnight fast revealed a signifi-
cant accumulation of  short-chain acyl-carnitines (SCAC) (containing 2–6 carbons) with a specific increase 
in C4 and Ci4 metabolites in cs-Lipin1–/– mice compared with WT controls (Figure 4A). The abundance of  
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medium-chain AC (MCAC) and long-chain AC (LCAC) tended to be increased but was not significantly 
greater. The abundance of  organic acids and amino acids was largely unaffected (Supplemental Table 1).
To evaluate mitochondrial function, LV cardiac tissue fibers were permeabilized, and mitochondrial 
respiration was assessed. Palmitoylcarnitine-mediated respiration was unaltered by the loss of  cardiac lipin 
1 (Figure 4B). In contrast, maximal pyruvate-mediated respiration and succinate-mediated respiration was 
lower in permeabilized strips from cs-Lipin1–/– mice (Figure 4B). Loss of  lipin 1 did not affect the mRNA 
expression (Figure 4C) or protein abundance (Figure 4D) of  components of  the electron transport chain or 
cytochrome C. We also did not detect reduced expression of  the components of  the pyruvate dehydroge-
nase (PDH) complex or increased inhibitory phosphorylation of  the PDH at Ser232 (Figure 4E). Collec-
tively, these data suggest that loss of  lipin 1 in the myocardium leads to reduced maximal respiration with 
pyruvate or succinate in association with reduced CL abundance.
Loss of  lipin 1 does not affect the response to transverse aortic constriction (TAC). To determine whether lipin 
deficiency caused the heart to be more sensitive to pathologic stimuli, we subjected WT and cs-Lpin1–/– 
Figure 2. cs-Lpin1–/– mice are viable and exhibit minimal cardiac phenotype at baseline. (A and B) Lipin 1 mRNA expression (A) and protein abundance (B) 
is significantly diminished in the hearts of cs-Lpin1–/– mice. (C) No difference was observed in biventricular weight between cs-Lpin1–/– mice and littermate 
controls. (D) cs-Lpin1–/– mice had increased expression of fetal program genes (Nppa, Nppb, Myh7, and Acta1). (E) Histologic findings were normal in the 
hearts of 10-week-old cs-Lpin1–/– mice. Scale bars: 1000 μm. (F) No differences in gene markers of autophagy or inflammation are seen in the hearts of 
cs-Lpin1–/– mice. (G) Electron micrographs reveal no differences in mitochondrial ultrastructure in the hearts of cs-Lpin1–/– mice. Scale bars: 200 nm. Data 
represent mean ± SEM. *P < 0.05 by ANOVA (n = 4–9/group).
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mice to pressure overload by the TAC surgical model. Deletion of  lipin 1 in the heart did not affect the 
hypertrophic response to TAC, as evidenced by an equivalent increase in LV wall thickness in systole (LVP-
Ws) and diastole (LVPWd) and an increase in the LV mass index (LVMI) (Table 2). Additionally, contrac-
tile function was unaltered by TAC as compared with WT mice in cs-Lipin–/– mice (Table 2).
Impaired ionotropic response and PKA signaling in cs-Lpin1–/– mice. We also assessed contractile reserve 
in cs-Lpin1–/– mice by closed chest cardiac catheterization studies. Hemodynamic measurements were 
obtained in response to increasing doses of  dobutamine. During the course of  the dobutamine infusion, 
heart rate was lower in cs-Lpin1–/– mice versus WT controls (Figure 5A). Isovolumic relaxation time (IVT), 
which typically declines with dobutamine, was higher in cs-Lpin1–/– mice compared with WT controls. Lip-
in 1 deficiency did not impact the effects of  dobutamine on ejection time, developed pressure, LV end-di-
astolic pressure, or negative dP/dt (Figure 5A). However, +dP/dt and the ratio of  +dP/dt to developed 
pressure increased in WT mice but was lower in cs-Lpin1–/– mice in response to increasing levels of  dobu-
tamine (Figure 5A). Collectively, these data suggest that loss of  lipin 1 leads to diminished cardiac reserve.
To test whether this was associated with functional effects on exercise endurance, which may be 
reduced in some patients with LPIN1 deficiency, WT and cs-Lpin1–/– mice underwent a graded intensity 
exercise bout on a motorized treadmill. We found that cs-Lpin1–/– mice ran for less time and distance com-
pared with WT littermate control mice (Figure 5B). This suggests that cardiac intrinsic effects of  lipin 1 
deficiency leads to reduced exercise capacity.
We have previously shown that lipin 1 deficiency in adipose tissue or liver leads to impaired PKA sig-
naling due to activation of  phosphodiesterase 4 in response to PA accumulation (19). Consistent with this, 
when cs-Lpin1–/– mice and littermate controls were injected with the β2 adrenergic agonist, clenbuterol, we 
found decreased phosphorylation of  several PKA targets in the hearts of  cs-Lpin1–/– mice compared with 
littermate mice, as assessed by a phospho-PKA substrate antibody (Figure 5C).
Discussion
Lipin 1 plays an important role in intermediary metabolism, but the effects of lipin 1 on cardiac metabolism and 
function remain poorly understood. Recent work conducted in patients with mutations in the gene encoding 
lipin 1 has suggested that some patients develop cardiac dysfunction and hemodynamic abnormalities when 
challenged with an increased workload (15). Magnetic resonance spectroscopic analyses of these hearts showed 
a paradoxical increase in cardiac triglyceride content. Herein, we show that mice with cardiac restricted lipin 1–
KO show a similar cardiac phenotype. Specifically, cardiac function is relatively normal at baseline, but the mice 
exhibit impaired contractility and cardiac reserve when challenged with dobutamine. Myocardial accumulation 
of several lipids, including PA, DAG, and triglyceride, was also noted. These mice can serve as a model for 
studying the cardiac effect of lipin 1 deficiency to further define mechanism and explore potential treatments.
Table 1. Echocardiographic parameters in WT and cs-Lpin1–/– mice
Males Females
WT cs-Lpin1–/– WT cs-Lpin1–/–
BW 21.38 ± 0.81 22.6 ± 0.53 18.3 ± 0.63 19.8 ± 0.27
HR 652.3 ± 9.01 639.1 ± 10.27 631.7 ± 3.18 622.0 ± 4.88
LVPWd 0.78 ± 0.018 0.81 ± 0.017 0.72 ± 0.038 0.75 ± 0.012
IVSd 0.78 ± 0.018 0.91 ± 0.016 0.73 ± 0.006 0.77 ± 0.014
LVIDd 3.27 ± 0.33 3.43 ± 0.087 3.067 ± 0.044 3.358 ± 0.072
LVPWs 1.38 ± 0.038 1.40 ± 0.029 1.31 ± 0.035 1.30 ± 0.025
IVSs 1.47 ± 0.17 1.51 ± 0.30 1.36 ± 0.02 1.38 ± 0.02
LVIDs 1.65 ± 0.49 1.67 ± 0.09 1.48 ± 0.04 1.73 ± 0.04
LVM 82.31 ± 2.69 96.08 ± 3.27 66.3 ± 3.02 81.6 ± 3.53
LVMI 3.87 ± 0.20 4.25 ± 0.11 3.7 ± 0.15 4.1 ± 0.14
RWT 0.48 ± 0.009 0.49 ± 0.018 0.48 ± 0.014 0.45 ± 0.008
FS 49.54 ± 0.99 51.40 ± 1.65 51.7 ± 1.99 48.5 ± 1.52
BW, body weight; HR, heart rate; LVPWd, left ventricular posterior wall diastole; IVSd, interventricular septum diastole; LVIDd, left ventricular internal 
diameter diastole; LVPWs, left ventricular posterior wall systole; IVSs, interventricular septum systole; LVIDs, left ventricular internal diameter systole; 
LVM, left ventricular mass; LVMI, left ventricular mass index (to body weight); RWT, relative wall thickness; FS, fractional shortening.
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Previous work on the effects of  lipin 1 on cardiac metabolism has employed fld mice, a model with 
spontaneous deletion of  lipin 1 (3). From these studies, it is clear that lipin 1 is the primary PAP enzyme 
in the heart (3, 4). While these studies have provided useful information, the interpretation of  the findings 
was complicated by the complex metabolic phenotype of  fld mice, which includes severe lipodystrophy and 
Figure 3. cs-Lpin1–/– mice exhibit cardiac lipid accumulation. (A–C) cs-Lpin1–/– mice have elevated levels of phos-
phatidic acid (A), diacylglycerol (B), and triacylglycerol (C) in their hearts compared with littermate controls. (D) Mass 
spectroscopy analysis displays reduced levels of cardiolipin in the hearts of cs-Lpin1–/– mice. Data represent mean ± 
SEM. *P < 0.05 by ANOVA (n = 4–6/group).
 
7
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(9):e134340  https://doi.org/10.1172/jci.insight.134340
metabolic abnormalities (6, 20); this led us to develop a cardiac-specific model. At 10 weeks of  age, fld mice 
exhibited reduced fractional shortening (3), whereas cardiac-specific deletion of  lipin 1 did not lead to overt 
systolic or diastolic function at baseline. One interpretation of  these results is that the systemic metabolic 
abnormalities of  fld mice impacted cardiac function. Indeed, cardiac dysfunction in fld mice was observed 
in vivo but not in vitro (3). However, it is not clear whether this relates well to the cardiac abnormalities in 
patients with LPIN1 mutations, since these patients are not lipodystrophic.
As in human patients with LPIN1 mutations (3), we observed cardiac DAG and triglyceride accumulation 
in lipin 1–deficient hearts. There are multiple lipin 1–independent pathways to synthesize DAG from phos-
pholipid that could explain this phenomenon, and this observation fits with the emerging concept that, in 
many tissues (9, 13, 14), lipin 1 is not required for normal rates of  triglyceride synthesis. It is possible that lipin 
1 PAP activity, instead, plays an important signaling role by regulating the abundance of  PA or other lipids. 
Figure 4. cs-Lpin1–/– hearts have decreased levels of ADP-stimulated mitochondrial respiration. (A) Metabolomic analysis revealed accumulation of 
short-chain acylcarnitines. (B) Mitochondrial respiration studies reveal a decreased response in cs-Lpin1–/– hearts in response to ADP-succinate–stim-
ulated respiration. (C) qPCR of analysis of cs-Lpin1–/– and WT cardiac muscle. (D) Western blot analysis showing protein expression of mitochondrial 
complexes (I–IV) and cytochrome C. (E) Western blot analysis of pyruvate dehydrogenase complex and phosphorylation of PDH in cardiac muscle of WT 
and cs-Lpin1–/– mice. Data represent mean ± SEM. *P < 0.05 by t test (n = 4–7/group).
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Indeed, a consistent observation in mice with KO of  lipin 1 is an attenuation of  PKA signaling. Adipo-
cyte-specific and liver-specific lipin 1–KO mice exhibit impaired PKA signaling (19), and this was also 
observed in the heart in the present study and by Kok and colleagues in fld mice (3). Mechanistically, PA 
accumulation due to lipin 1 deficiency activates phosphodiesterase 4, which degrades cAMP to attenuate 
PKA signaling (19). Consistent with a decline in PKA activity, fld mice are also reported to have reduced 
phosphorylation of  hormone sensitive lipase, an exemplar PKA target, in heart (3) and adipose tissue (19). 
Alterations in PKA-stimulated lipolysis through this pathway could also contribute to the accumulation of  
DAG and triglyceride in cs-Lpin1–/– hearts by reducing turnover of  these lipids.
Also consistent with impaired PKA signaling, cardiac reserve was reduced in the KO mice during 
inotropic stimulation. It is also possible that the attenuated response to dobutamine could be energetic in 
nature, since mitochondrial respiration was impaired in mice with cardiac lipin 1 KO. We did not detect 
any abnormalities in mitochondrial mass or protein abundance, which is different than skeletal muscle 
of  lipin 1–deficient mice (14), but we did find that the abundance of  CL, a phospholipid found in the 
inner mitochondrial membrane, was reduced in lipin 1–deficient hearts. CL is derived from PA but does 
not require PAP activity to be synthesized (Figure 1A). Deficiency in CL leads to Barth syndrome, which 
is associated with cardiac defects due to mitochondrial abnormalities (21). Nonetheless, these mitochon-
drial abnormalities were much less severe than the mitochondrial phenotype observed in skeletal muscle 
(14). The myopathy observed in lipin 1–deficient skeletal myocytes was also not observed in cardiac myo-
cytes. The mechanistic explanation for the tissue-specific effects of  lipin 1 deficiency on mitochondrial 
function and myocyte viability remains to be determined.
We have previously demonstrated that lipin 1 protein abundance is diminished in mouse models of  
heart failure coincident with accumulation of  PA in the myocardium (4). Herein, we demonstrate that lipin 
Table 2. Echocardiographic parameters in WT and cs-Lpin1–/– mice after transaortic constriction or sham surgery
Sham TAC
WT cs-Lpin1–/– WT cs-Lpin1–/–
BW 25.15 ± 2.15 26.15 ± 2.05 25.22 ± 0.54 25.70 ± 0.67
HR 652.0 ± 3.00 664.5 ± 21.50 654.6 ± 13.24 627.8 ± 16.49
LVPWd 0.80 ± 0.06 0.80 ± 0.03 1.06 ± 0.08 1.09 ± 0.03
IVSd 0.81 ± 0.04 0.86 ± 0.01 1.05 ± 0.08 1.17 ± 0.03
LVIDd 3.68 ± 0.15 3.69 ± 0.12 3.70 ± 0.15 3.60 ± 0.12
LVPWs 1.31 ± 0.03 1.50 ± 0.05 1.49 ± 0.05 1.46 ± 0.05
IVSs 1.48 ± 0.14 1.34 ± 0.13 1.56 ± 0.08 1.66 ± 0.05
LVIDs 1.84 ± 0.14 1.92 ± 0.01 2.38 ± 0.29 2.35 ± 0.14
LVM 102.42 ± 15.02 106.92 ± 7.16 156.19 ± 21.51 160.48 ± 6.98
LVMI 4.05 ± 0.25 4.09 ± 0.05 6.18 ± 0.82 6.26 ± 0.33
RWT 0.44 ± 0.01 0.45 ± 0.01 0.57 ± 0.04 0.63 ± 0.03
FS 50.07 ± 1.77 47.85 ± 1.36 36.52 ± 5.43 34.93 ± 2.46
E 664.0 ± 70.0 858.0 ± 28.0 980.20 ± 44.13 926.4 ± 21.04
S′ 28.28 ± 0.60 31.88 ± 3.61 27.07 ± 0.91 28.15 ± 1.63
E′ 25.87 ± 8.42 35.20 ± 1.51 31.13 ± 3.64 24.19 ± 3.46
E/E′ 29.69 ± 12.37 24.39 ± 0.25 33.41 ± 3.07 40.73 ± 4.31
IVCT 7.08 ± 1.25 4.84 ± 0.36 7.76 ± 1.04 7.51 ± 0.76
ET 34.80 ± 1.88 32.43 ± 2.77 40.76 ± 2.65 39.79 ± 0.95
IVRT 12.09 ± 1.66 11.01 ± 1.41 11.78 ± 0.64 14.22 ± 1.64
Tei Index 0.55 ± 0.05 0.49 ± 0.07 0.48 ± 0.03 0.55 ± 0.06
AO VTI 31.63 ± 1.41 34.37 ± 1.48 229.29 ± 59.55 258.79 ± 30.92
LVOT VTI 45.40 ± 12.18 37.63 ± 5.30 41.65 ± 2.65 38.76 ± 3.56
VTI ratio 0.74 ± 0.17 0.94 ± 0.17 5.63 ± 1.38 6.77 ± 0.75
Mean gradient 1.40 ± 0.12 1.70 ± 0.48 33.81 ± 9.83 41.44 ± 6.00
Peak velocity 1.24 ± 0.09 1.34 ± 0.16 4.68 ± 0.88 5.52 ± 0.33
E, Peak velocity of early diastolic transmitral flow; S′, Peak velocity of systolic mitral annular motion; E′, peak velocity of early diastolic mitral annular 
motion; IVCT, isovolumic contraction time; IVRT, isovolumic relaxation time; AO VTI, aortic velocity time integral at constriction site; LVOT VTI, left 
ventricular outflow tract velocity time integral.
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1 is also deactivated in failing human heart. Although there was insufficient sample mass to quantify PA or 
other lipids in these samples, it is likely that PA may be increased in these samples, as it is in failing mouse 
heart. It remains to be determined whether reduced lipin 1 activity and accumulation of  PA affects cardiac 
contractility in failing heart. While the cs-Lpin1–/– mice did not exhibit cardiac dysfunction after TAC sur-
gery, it is probable that a lipin 1 gain-of-function approach might be the better way to test the role of  lipin 1 
in heart failure, since lipin 1 is deactivated by pathologic stimuli.
In conclusion, these studies define cardiac-specific roles for lipin 1 in regulating cardiac lipid levels and 
cardiac reserve in response to functionally demanding stimuli. However, mice with cardiac deletion of  lipin 
1 did not exhibit a propensity to develop heart failure after TAC — a pathologic stimulus that can cause mice 
with mild cardiomyopathy to develop overt dysfunction. These findings may have implications for the rare 
patients with LPIN1 mutations, as well as general impact for metabolic adaptations that occur in failing heart. 
Figure 5. cs-Lpin1–/– mice exhibit reduced response to β-agonist stimulation. (A) Dobutamine stimulation during 
cardiac catheterization to measure HR, IVT, +dP/dt, and (dP/dt)/developed pressure. Data represent mean ± SD. *P 
< 0.05 by repeated-measures ANOVA (n = 4–6/group). (B) Graphs depict distance run and time to exhaustion during 
forced treadmill exercise studies (n = 7 per group). *P < 0.05 by t test. (C) Western blot analysis of P-PKA substrates in 
response to clenbuterol stimulation.
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Future work will continue to examine the effects of  lipin 1 deficiency on metabolism and function and will 
provide further insight into the molecular mechanisms involved.
Methods
Human heart samples. Failing human LV tissue was obtained from the Washington University Translational 
Cardiovascular Tissue Core at the time of  LVAD placement. Nonfailing control heart tissue was obtained 
from Mid-America Transplant (St. Louis, Missouri, USA) from hearts deemed unsuitable for transplanta-
tion due to donor age, coronary artery disease, or high-risk behavioral profile. The collected piece of  cardiac 
tissue was trimmed, rinsed in saline, and then frozen in liquid nitrogen and stored at –80°C until analyzed.
Generation of  cs-Lpin1–/– mice. The generation of  Lpin1-floxed mice was recently described (14). Homo-
zygous Lpin1-floxed mice (B6[Cg]-Lpin1tm1c[EUCOMM]Hmgu/FincJ; The Jackson Laboratory, stock no. 
032117) in the C57BL/6J background were crossed with mice expressing Cre recombinase under the 
endogenous myosin light chain 2v promoter (B6.129S4[Cg]-Myl2tm1[cre]Krc/AchakJ; The Jackson Laborato-
ry, stock no. 029465) to homozygosity for the Lpin1-floxed allele. Littermates not expressing Cre (WT mice) 
were used as control mice in all experiments. Fld mice in the BALB/C background, used as a negative 
control in Figure 2B, were also obtained from The Jackson Laboratory (BALB/cByJ-Lpin1fld/J; stock no. 
001592). Mice were studied at 10–16 weeks of  age, and both sexes of  mice were studied as indicated.
Western blotting. Protein from frozen heart tissue was homogenized in 1 mL ice-cold lysis buffer (20 mM 
Tris, 15 mM NaCl, 1 mM EDTA, 0.2% NP-40, 10% glycerol, supplemented with 1 mM activated Na3VO4, 
1 mM phenylmethanesulfonyl fluoride, 5 mM sodium fluoride (all from MilliporeSigma), and 1× Com-
plete protease inhibitor cocktail tablet; Roche) using high-speed tissue disruption with a stainless steel bead 
and the TissueLyser II (Qiagen). Lysates were then rotated at 4°C for 1 hour. Samples were then centri-
fuged (15,000g for 15 minutes at 4°C), and supernatants were transferred to a new microfuge tube. Protein 
quantification was performed using the bicinchoninic acid (BCA) assay according to the manufacturer’s 
protocol (Pierce Biotechnology). The remaining lysates were aliquoted (to prevent repeated freeze-thaw 
cycles) and stored at –80°C. Lysates were subjected to PAGE analysis using Criterion precast gels (Bio-Rad) 
and were then transferred to PVDF membranes. The blots were blocked in 5% BSA/1× TBST for 1 hour 
at room temperature and were incubated overnight (4°C with rocking) with the appropriate primary anti-
body: lipin 1 (sc-98450, Santa Cruz Biotechnology Inc.); OXPHOS (MS604-300, Abcam); PDH pSer232 
(AP1063, MilliporeSigma); PDH (ab110416, Abcam); cytochrome C (ab110325, Abcam); phospho-PKA 
substrate (RRXS/T; 9624, Cell Signaling Technology), and tubulin (T5168, Sigma-Aldrich). Blots were 
then washed 3× in TBST and incubated with appropriate secondary antibodies: goat anti–rabbit IRDye 680 
(catalog 926-68021) or goat anti–mouse IRDye 680 (catalog 926-32220) (both from Li-Cor Biosciences) for 
1 hour at room temperature; they were washed again 3× in TBST and imaged with the Odyssey Imaging 
System (Li-Cor Biosciences).
Quantitative PCR. Total RNA was isolated from hearts using the RNAzol method (RNA-Bee; Tel-Test). 
Complementary DNA was synthesized by using a high-capacity reverse transcription kit (Applied BioSyste-
ms). Real-time PCR was performed using an ABI PRISM 7500 sequence detection system and a SYBR green 
master mix (Applied BioSystems). Primer sequences can be found in Supplemental Table 2. Arbitrary units of  
target cDNA were normalized to the levels of  the housekeeping gene 36B4 cDNA. Oligonucleotide sequences 
are found in Supplemental Table 2.
Lipid analysis. The abundance of  PA, DAG, triglyceride, and CL in mouse hearts was determined as 
described with modification (22). The LC-MS analysis was performed either with a Shimadzu 10A HPLC 
system and a Shimadzu SIL-20AC HT auto-sampler coupled to a Thermo Scientific TSQ Quantum Ultra 
triple quadrupole (TQ) mass spectrometer operated in selected reaction monitoring mode or with a Ther-
mo Fisher Scientific Vantage TSQ mass spectrometer with Thermo Accela UPLC operated by Xcalibur 
software using selected ion monitoring mode. PA-(14:0)2, DAG-(15:0)2, triglyceride-(17:0)3, and CL-(14:0-
14:0)2 were used as internal standards. Quantification of  lipids was based on the ratio of  the peak area of  
the analyte to the internal standard. For example, the ratio of  CL-(18:2/18:2)2 and CL-(14:0-14:0)2 is used 
for measurement of  CL-(18:2/18:2)2.
Metabolomics analysis. Mice used for targeted metabolomic analyses were fasted for 18 hours, deep-
ly anesthetized with isoflurane inhalation, and euthanized by excision of  the beating heart. Hearts were 
freeze clamped with frozen tongs, frozen in liquid nitrogen, and stored at –80°C until they were collectively 
processed and analyzed. Flash-frozen hearts were pulverized to a fine powder in a liquid nitrogen–chilled 
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percussion mortar and pestle and were weighed into prechilled 2 mL tubes. A chilled 5 mm homogenizing 
bead was added to samples, and tissue was diluted to 50 mg/mL with 50% acetonitrile containing 0.3% 
formate, homogenized for 2 minutes at 30 Hz using a TissueLyser II (Qiagen), and aliquoted for metabolite 
assays. For all metabolite analyses, tissues and homogenates were kept on ice, centrifuged at 4°C, and — 
when ready to measure — were placed in an autosampler kept at 4°C.
Amino acids and acylcarnitines were analyzed by flow injection electrospray ionization tandem mass 
spectrometry and quantified by isotope or pseudoisotope dilution. Extracted heart samples were spiked 
with a cocktail of  heavy-isotope internal standards (Cambridge Isotope Laboratories; or CDN Isotopes) 
and deproteinated with methanol. The methanol supernatants were dried and esterified with either acidi-
fied methanol or butanol for acylcarnitine or amino acid analysis, respectively. Mass spectra for acylcarni-
tine and amino acid esters were obtained using precursor ion and neutral loss scanning methods, respec-
tively. The spectra were acquired in a multichannel analyzer (MCA) mode to improve the signal-to-noise 
ratio. The data were generated using a Waters TQ detector equipped with Acquity UPLC system and a data 
system controlled by MassLynx 4.1 operating system (Waters). Ion ratios of  analyte to a respective internal 
standard computed from centroided spectra were converted to concentrations using calibrators constructed 
from authentic aliphatic acylcarnitines and amino acids (MilliporeSigma; Larodan), as well as Dialyzed 
Fetal Bovine Serum (MilliporeSigma).
Organic acids were analyzed by capillary gas chromatography/mass spectrometry (GC/MS) using iso-
tope dilution techniques employing Trace Ultra GC coupled to ISQ MS operating under Xcalibur 2.2 (Ther-
mo Fisher Scientific). The supernatants of  tissue homogenates were spiked with a mixture of  heavy iso-
tope–labeled internal standards, and the keto acids were stabilized by ethoximation. The organic acids were 
acidified and extracted into ethyl acetate. The extracts were dried and derivatized with N,O-bis(Trimethylsi-
lyl) trifluoroacetamide. The organic acids were quantified using ion ratios determined from single ion record-
ings of  fragment ions, which are specific for a given analyte and its internal standard. These ratios were 
converted to concentrations using calibrators constructed from authentic organic acids (MilliporeSigma).
Transverse aortic constriction. Surgery was performed by the Mouse Cardiovascular Phenotyping 
Core (MCPC) at Washington University School of  Medicine. In brief, mice were anesthetized with a 
mixture of  xylazine (10 mg/kg) and ketamine (100 mg/kg), and the TAC procedure was performed by 
a surgeon blinded to the genotype of  the mice as described (23). Following 2 weeks of  pressure over-
load using TAC, the animals underwent 2-D echocardiographic imaging for LV structure and function. 
The day after Echo analysis, the mice were euthanized, and the hearts were excised for heart weight/
body weight ratio; they were then were snap frozen for further analyses.
Hemodynamics. WT and cs-Lpin1–/– mice underwent in vivo hemodynamic evaluations using a graded 
dobutamine infusion to assess cardiac reserve as described (24). These studies were also carried out by 
the MCPC. Briefly, mice were anesthetized with 2% isoflurane and were maintained on 1.5% isoflurane 
throughout the duration of  the procedure. Closed chest cardiac catheterization was performed by identify-
ing and cannulating the right carotid artery, and a 1.4 Fr Scisense catheter was advanced into the ascending 
aorta, and then retrograde across the valve into the left ventricle. After acquiring baseline measurements, 
dobutamine was serially infused at rates of  4, 8, 16, and 32 ng/g BW/min. Hemodynamic measurements 
were then recorded in real time and analyzed offline.
Exercise protocol. For exercise studies, male mice were run to exhaustion on a closed 6-lane treadmill (Colum-
bus Instruments) equipped with a shock grid at the back of each belt that delivered a mild electrical stimulus to 
encourage continuous running. Food was removed 5 hours before exercise, water was available ad libitum, and 
bedding was replaced with Aspen chip bedding. Mice were acclimated to the treadmill with 0° incline at 0 m/
min for 5 minutes. The speed was then increased to 5 m/min and maintained for 5 minutes. After 5 minutes of  
continuous running, the speed was increased so that, after the first 5 minutes, the speed reached 10 m/min, 5 
minutes later the speed reached 15 m/min, and so on, until mice reached exhaustion. Speeds did not exceed 30 
m/min. Exhaustion was determined by refusal of mice to remain on the treadmill belt for 10 seconds.
Echocardiography. Two-dimensional M-mode echocardiography was performed by the MCPC using a 
VEVO 2100 ultrasound machine. Mice were anesthetized with Avertin, which preserves the heart rate at 
physiologic levels throughout the imaging protocol. All echocardiography was performed by an investiga-
tor who was blinded to genotype.
Mitochondrial respiration. LV cardiac tissue was permeabilized with saponin (5 mg/mL), and high-reso-
lution respirometry was conducted using an Oxygraph O2k (Oroboros Instruments). A total of  3–4 mg of  
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permeabilized tissue was added to 2 mL of  MiR05 (Oroboros) respiration buffer supplemented with creatine 
and blebbistatin. Respiratory substrates utilized were malate (2 mM), pyruvate (5 mM), palmitoyl-carnitine 
(10 mM), ADP (2 mM), succinate (10 mM), FCCP (0.5 μM, repeated injections until maximal respiration 
occurred), and rotenone (0.5 μM). All measures were normalized to tissue weight.
Statistics. Statistical comparisons were made using a 2-tailed Student’s t test or 2-way ANOVA with 
Tukey’s post hoc analysis performed where appropriate. All data, unless otherwise noted, are presented as 
mean ± SEM. P ≤ 0.05 WAS considered statistically significant.
Study approval. All animal experiments were approved by the IACUC of  Washington University. 
Human heart samples were collected with written informed consent received from participants as part of  
an IRB-approved protocol at the Washington University School of  Medicine.
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